PNAS:预测皮肤癌风险新方法!依赖于紫外线敏感的“超热点”

2019-11-19 佚名 生物探索

紫外线辐射是造成皮肤癌的主要原因,筛选超热点将使测量一个人过去的紫外线暴露更加容易,可能会提供一种预测人的皮肤癌风险的新方法。

耶鲁大学科学家的一项新研究报告说,在人类基因组中发现了“超热点”,该位点对太阳光中的紫外线辐射(UV)的敏感度与平均水平相比高达170倍。

紫外线辐射是造成皮肤癌的主要原因,筛选超热点将使测量一个人过去的紫外线暴露更加容易,可能会提供一种预测人的皮肤癌风险的新方法。该研究发表在《PNAS》上。

这种超热点被称为“环丁烷嘧啶二聚体(CPD)超热点”,是由紫外线引起的DNA损伤类型,可被视为吸引有害辐射的“靶心”,最常见于负责皮肤和头发颜色的人类黑素细胞,大约包含2,000多个这样的位点。

“我们曾认为导致癌症的DNA损伤和突变是罕见且随机的,” 该研究的领导者、耶鲁大学癌症研究中心的科学家Douglas Brash说。“但我们的研究表明,至少对于皮肤癌来说,基因组中有特定的靶标正在等待被紫外线辐射击中。”



AdductSeq方法,用于在整个基因组中以单碱基分辨率定量CPD

为了找到它们,研究人员设计了一种标记CPD位点的方法AdductSeq,并使用高通量DNA测序在整个基因组中定位标记。他们还开发了一套统计方法,用于量化单个位点相对于基因组平均值的CPD过量表达。

在晒伤的UVB暴露水平下,每个超热点都会在多达1%的黑素细胞中获得CPD。

在紫外线照射下,超热点获得CPD的频率比基因组平均频率高170倍,它们位于基因附近的特定位置,是紫外线辐射损害细胞的直接途径。正如先前所认为的那样,一个人会实时地、经历紫外线辐射引起的特定细胞生长畸变,而不是随机、不可预测地,并且也不会在数周或数年后经历畸变。

Brash说,进化并没有消除这些不利因素,这可能暗示细胞利用超热点来感知其环境。超热点的存在表明,由致癌物(紫外线或其他辐射)引起的突变也不是完全随机的,黑色素瘤中与基因调控相关的突变在CPD超热点的发生频率是其他地方的20,000倍。

这项研究同时还提出了评估皮肤癌风险的新方法。评估皮肤癌风险最重要的因素是先前的紫外线照射,但是医生目前缺乏客观的测量方法,通常依靠患者对以前晒伤的记忆。研究人员表示,如果医生可以采集少量皮肤样本并检查超热点,那么他们可以真实地了解这些部位先前晒伤后的DNA损伤情况,并对患者的接触史和皮肤癌风险有更好的了解,以便在可以治愈的情况下及早发现皮肤癌。

原始出处:

Sanjay Premi et al, Genomic sites hypersensitive to ultraviolet radiation, Proceedings of the National Academy of Sciences (2019). DOI: 10.1073/pnas.1907860116.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1856361, encodeId=31da18563616e, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Feb 09 04:44:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981022, encodeId=b33b198102281, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jan 27 01:44:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903387, encodeId=6717190338eb6, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jul 09 12:44:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061894, encodeId=56fe206189430, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Feb 02 13:44:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-02-09 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1856361, encodeId=31da18563616e, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Feb 09 04:44:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981022, encodeId=b33b198102281, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jan 27 01:44:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903387, encodeId=6717190338eb6, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jul 09 12:44:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061894, encodeId=56fe206189430, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Feb 02 13:44:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1856361, encodeId=31da18563616e, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Feb 09 04:44:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981022, encodeId=b33b198102281, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jan 27 01:44:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903387, encodeId=6717190338eb6, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jul 09 12:44:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061894, encodeId=56fe206189430, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Feb 02 13:44:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1856361, encodeId=31da18563616e, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Feb 09 04:44:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981022, encodeId=b33b198102281, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jan 27 01:44:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903387, encodeId=6717190338eb6, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jul 09 12:44:00 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061894, encodeId=56fe206189430, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Feb 02 13:44:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-02-02 sjq027

相关资讯

欧盟批准赛诺菲的PD-1单抗Libtayo用于治疗皮肤癌

赛诺菲宣布欧盟批准其全人源免疫检查点受体PD-1(程序性细胞死亡蛋白-1)单抗Libtayo(cemiplimab)用于治疗转移性或局部晚期、不适合进行手术或放射治疗的皮肤鳞状细胞癌(CSCC)成年患者。

Brit J Cancer:氢氯噻嗪与皮肤癌风险

由此可见,在亚洲人群中使用氢氯噻嗪似乎对皮肤癌风险是安全的。

Nature:第一个证据!共生HPV病毒或可预防皮肤癌

CD45+白细胞(灰色)和CD3+T细胞(黄色)攻击感染了共生乳头瘤病毒的癌细胞(红色)。图片来源:Jonathan L. Messerschmidt北京时间10月31日,发表在《Nature》上的一项新研究显示,病毒虽作为潜在的癌症制造者而人人避恐不及,但至少有一类生活在我们皮肤上的病毒,即所谓的“低风险”病毒——人类乳头状瘤(HPV),似乎在保护我们免受皮肤癌的侵害。已知免疫系统受到疾病或药物

Nature:HPV免疫应答可抵御皮肤癌

免疫应答遭到抑制,很有可能增加罹患病毒感染相关的肿瘤的概率。有报道指出,皮肤鳞状细胞癌(squamous cell carcinoma,简称SCC)与beta型人类乳头瘤病毒(beta human papillomavirus,简称β-HPV)相关,而免疫应答受到抑制的病人,罹患此种肿瘤的概率是健康人群的一百倍以上。但是,学界对于皮肤癌与HPV之间的因果关系并没有给出明确的答案。

JAMA Dermatol:维生素A摄入量与皮肤鳞状细胞癌风险的关系

类视黄醇是维生素A的生物活性形式,其对维持上皮成熟和分化至关重要。合成类视黄醇被用于具有潜在不利影响的高风险人群中的皮肤癌的化学预防。

Nat Commun:部分皮肤癌可能起源于毛囊

一项新的研究发现,一些致命的皮肤癌可能是由毛囊干细胞,而非皮肤细胞恶化产生的。